多重耐药耳念珠菌在三大洲同时出现:全基因组测序与流行病学分析
该研究对2012—2015年来自巴基斯坦、印度、南非和委内瑞拉的54株耳念珠菌临床分离株及日本模式株进行抗真菌药敏试验和全基因组测序。结果显示93%对氟康唑耐药、35%对两性霉素B耐药、7%对棘白菌素类耐药,41%对两类耐药、4%对三类耐药;全基因组测序显示分离株按地理区域形成独特克隆群,提示三大洲近期几乎同时独立出现不同克隆种群。
要点
- 耳念珠菌是新兴医疗相关病原体,血流感染占61%,死亡率达59%。
- 耐药普遍:93%耐氟康唑、35%耐两性霉素B、7%耐棘白菌素类。
- 全基因组测序证实地理分隔的克隆群,提示三大洲独立近期出现。
核心结论
- 耳念珠菌是新兴医疗相关病原体,与高死亡率相关,因抗真菌耐药导致治疗选择有限。
- 全基因组测序分析提示不同克隆种群在三大洲几乎同时且近期独立出现。
研究设计与样本
- 获取2012—2015年来自巴基斯坦、印度、南非和委内瑞拉的54例耳念珠菌感染患者分离株及日本模式株。
- 对41株分离株有患者信息,进行抗真菌药敏试验和全基因组测序。
主要发现
- 41%患者有糖尿病,51%近期接受手术,73%留置中心静脉导管,41%分离出耳念珠菌时正接受全身抗真菌治疗。
- 入院至感染中位时间19天(四分位距9—36天),61%患者为血流感染,59%死亡。
- 采用严格折点,93%分离株对氟康唑耐药、35%对两性霉素B耐药、7%对棘白菌素类耐药;41%对两类耐药、4%对三类耐药。
- 全基因组测序显示分离株按地理区域分组为独特克隆群,克隆群间相差数千个单核苷酸多态性,但各克隆群内分离株呈克隆性。
- 各地理克隆群中,ERG11不同突变与唑类耐药相关。
关键数值与推荐
- 采用严格折点判定耐药:氟康唑耐药93%、两性霉素B耐药35%、棘白菌素类耐药7%。
- 41%分离株对2类抗真菌药耐药,4%对3类耐药。
临床怎么用
- 对耳念珠菌感染需考虑多重耐药可能,治疗选择有限。
- 需明确风险因素和传播机制以指导感染控制措施。
局限性
- 仅41株分离株有患者临床信息。
- 风险因素和传播机制尚需进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
引用
- Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2016. PMID: 27988485. doi:10.1093/cid/ciw691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。